Edoxaban tosylate monohydrate

• CAT Number: I006593
• CAS Number: 1229194-11-9 (tosylate hydrate)
• Molecular Formula: C31H40ClN7O8S2
• Molecular Weight: 738.272
• Purity: ≥95%
• Target: factor Xa inhibitor
• Solubility: Soluble in DMSO.
• Storage: 0 - 4°C for short term or -20 °C for long term
• IUPAC Name: N/'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide;4-methylbenzenesulfonic acid;hydrate
• InChI: InChI=1S/C24H30ClN7O4S.C7H8O3S.H2O/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10;/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10);1H2/t13-,15-,17+;;/m0../s1
• InChIKey: PSMMNJNZVZZNOI-SJILXJHISA-N
• SMILES: CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O

Edoxaban (INN, codenamed DU-176b, trade name Lixiana) is a potent, selective factor Xa inhibitor, which has good oral bioavailability. Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is being developed by Daiichi Sankyo. It was approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism.

Reference

1:J Am Pharm Assoc (2003). 2015 Sep-Oct;55(5):563-7. doi: 10.1331/JAPhA.2015.15537. Edoxaban tosylate monohydrate, secukinumab, and suvorexant.Hussar DA,Jacob J, PMID: 26359966 DOI: 10.1331/JAPhA.2015.15537